Pharmacokinetics of isoniazid and rifampin in adults with tuberculosis.

被引：0
|
作者：
Auclair, B
Burman, WJ
Stambaugh, JJ
Berning, SE
Ashkin, D
Peloquin, CA
机构：
[1] Natl Jewish, Denver, CO USA
[2] Denver Publ Hlth, Denver, CO USA
[3] AG Holley Hosp, Lantana, FL USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 1999年 / 159卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：A495 / A495
页数：1
相关论文
共 50 条
  • [21] Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months
    Nolan, CM
    Goldberg, SV
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2002, 6 (11) : 952 - 958
  • [22] HEPATOTOXICITY FROM ISONIAZID AND RIFAMPIN AMONG CHILDREN TREATED FOR TUBERCULOSIS
    OBRIEN, RJ
    LONG, MW
    CROSS, FS
    LYLE, MA
    SNIDER, DE
    PEDIATRICS, 1983, 72 (04) : 491 - 499
  • [23] Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan
    Hofmann-Thiel, S.
    van Ingen, J.
    Feldmann, K.
    Turaev, L.
    Uzakova, G. T.
    Murmusaeva, G.
    van Soolingen, D.
    Hoffmann, H.
    EUROPEAN RESPIRATORY JOURNAL, 2009, 33 (02) : 368 - 374
  • [24] The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis
    Akos Somoskovi
    Linda M Parsons
    Max Salfinger
    Respiratory Research, 2
  • [25] TREATMENT OF 171 PATIENTS WITH PULMONARY TUBERCULOSIS RESISTANT TO ISONIAZID AND RIFAMPIN
    GOBLE, M
    ISEMAN, MD
    MADSEN, LA
    WAITE, D
    ACKERSON, L
    HORSBURGH, CR
    NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (08): : 527 - 532
  • [26] Rapid desensitization to isoniazid and rifampin in an adolescent with active pulmonary tuberculosis
    Lee, Heirim
    Kim, Min-Sun
    Yang, Hea-Kyoung
    Kim, Minji
    Lee, Ji Young
    Kim, Jong-Min
    Kang, Ji-Man
    Kim, Yae-Jean
    Ahn, Kangmo
    Kim, Jihyun
    ALLERGY ASTHMA & RESPIRATORY DISEASE, 2016, 4 (03): : 212 - 216
  • [27] The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis
    Somoskovi, A
    Parsons, LM
    Salfinger, M
    RESPIRATORY RESEARCH, 2001, 2 (03) : 164 - 168
  • [28] COST EFFECTIVENESS ANALYSIS TO TREAT LATENT TUBERCULOSIS INFECTION: CAMPARING ISONIAZID, RIFAMPIN AND RIFAMPIN/PYRAZINAMIDE
    Sangani, D.
    VALUE IN HEALTH, 2010, 13 (03) : A191 - A191
  • [29] Minimum inhibitory concentrations of rifampin and isoniazid among multidrug and isoniazid resistant Mycobacterium tuberculosis in Ethiopia
    Getahun, Muluwork
    Blumberg, Henry M.
    Ameni, Gobena
    Beyene, Dereje
    Kempker, Russell R.
    PLOS ONE, 2022, 17 (09):
  • [30] RIFAMPIN-INDUCED RELEASE OF HYDRAZINE FROM ISONIAZID - A POSSIBLE CAUSE OF HEPATITIS DURING TREATMENT OF TUBERCULOSIS WITH REGIMENS CONTAINING ISONIAZID AND RIFAMPIN
    SARMA, GR
    IMMANUEL, C
    KAILASAM, S
    NARAYANA, ASL
    VENKATESAN, P
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1986, 133 (06): : 1072 - 1075
12345